Delivery systems and molecular targets of mechanism-based therapies for GBM

Expert Review of Neurotherapeutics

Volumn 4, Issue 4, 2004, Pages 649-663

  Phuphanich, Surasak ^a   Brat, Daniel J ^b   Olson, Jeffrey J ^c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

De novo adenosine synthesis inhibitors; Endothelin receptor antagonist; Farnesyltransferase inhibitors; Glioblastoma multiforme; Interleukin 13; Local convection enhanced drug delivery; Pseudomonas exotoxin; TP 38 toxin; Tyrosine kinase inhibitors

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 5' METHYLTHIOADENOSINE PHOSPHORYLASE; ADENOSINE; ATRASENTAN; BB 251; BORTEZOMIB; CC 5103; CELECOXIB; CETUXIMAB; CILENGITIDE; ENDOTHELIN RECEPTOR ANTAGONIST; ERLOTINIB; GEFITINIB; IMATINIB; IMID; LONAFARNIB; MARIMASTAT; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN DERIVATIVE; SDX 102; SEMAXANIB; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VATALANIB;

ANGIOGENESIS; CANCER CLASSIFICATION; CHROMOSOME 19Q; CHROMOSOME 1P; CHRONIC DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENOMICS; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; MOLECULAR TARGET; ONCOGENE RAS; PROTEOMICS; PTEN GENE; REVIEW; TP53 GENE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GLIOBLASTOMA; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 3042826830     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.4.649     Document Type: Review

References (143)

1. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Central Brain Tumor Registry of the United States. Chicago, IL, USA (2002). Good report on the incidence of primary benign and malignant brain tumor.
2. Levin VA, Uhm JH, Jaeckle KA et al. Phase III randomized study of postradiotherapy chemotherapy with α-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin. Cancer Res. 6, 3878-3884 (2000).
3. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: Cancer: Principles and Practice of Oncology. Sixth Edition. DeVita VTJ, Hellman S, Rosenberg SA (Eds). Lippincott-Raven, PA, USA, 2100-2160 (2001).
4. DeAngelis LM, Burger PC, Green SB et al. Malignant glioma: who benefits from adjuvant chemotherapy? Ann. Neurol. 44, 691-695 (1998).
5. Bailey P, Cushing HA. Classification of Tumors of the Glioma Group. Lippincott, PA, USA (1926).
6. Burger P, Scheitauer BW. Tumors of the Central Nervous System. Forces Institute of Pathology, Washington DC, USA (1994).
7. Kleihues P, Cavenee W. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. International Agency for Research on Cancer. IARC Press, Lyon, France (2000).
8. Cavenee WK, Furnari FB, Nagane M et al. Infiltrating astrocytomas. In: Pathology and Genetics of Tumours of the Nervous System. Second Edition. Kleihues P, Cavenee WK (Eds). International Agency for Research on Cancer. International Agency for Research, Lyon, France, 10-21 (2000).
9. Reifenberger G, Kros JM, Burger PC et al. Oligodendroglioma. In: Pathology and Genetics of Tumors of the Nervous System. Second Edition. Kleihues P, Cavenee WK, (Eds). International Agency for Research on Cancer. IARC Press, Lyon, France, 56-61 (2000).
10. Reifenberger G, Kros JM, Burger PC et al. Anaplastic oligodendroglioma. In: Pathology and Genetics of Tumors of the Nervous System. Second Edition Kleihues P, Cavenee WK, (Eds). International Agency for Research on Cancer. IARC Press, Lyon, France, 62-64 (2000).
11. Reifenberger G, Kros JM, Burger PC et al. Anaplastic oligodendroglioma. In: Pathology and Genetics of Tumors of the Nervous System. Second Edition Kleihues P, Cavenee WK, (Eds). International Agency for Research on Cancer. IARC Press, Lyon, France, 65-67 (2000).
12. Reifenberger G, Kros JM, Burger PC et al. Anaplastic oligodendroglioma. In: Pathology and Genetics of Tumors of the Nervous System. Second Edition Kleihues P, Cavenee WK, (Eds). International Agency for Research on Cancer. IARC Press, Lyon, France, 68-69 (2000).
13. Coons SW, Johnson PC, Scheithauer BW et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79, 1381-1393 (1997). Demonstrates the high degree of interobserver variability in diagnostic neuropathology indicating a need for improved molecular methods for classification.
14. Fulci G, Ishii N, Van Meir EG et al. p53 and brain tumors: from gene mutations to gene therapy, Brain Pathol. 8, 599-613 (1998).
15. Hunter SB, Brat DJ, Olson JJ et al. Alterations in molecular pathways of diffusely infiltrating astrocytomas: application to tumor classification and antitumor therapy. Int. J. Oncol. 23, 857-869 (2003).
16. Reifenberger G, Liu L, Ichimura K et al. Amplification and over expression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations, Cancer Res. 53, 2736-2739 (1993).
17. Fulci G, Labuhn M, Maier D et al. EG. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19, 3816-3822 (2000).
18. Nakamura M, Watanabe T, Klangby U et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 11, 159-168 (2001).
19. Schmidt MC, Antweiler S, Urban N et al. Impact of genotype and morphology on the prognosis of glioblastoma. J. Neuropathol. Exp. Neurol. 61, 321-328 (2002).
20. Smith JS, Tachibana I, Passe SM et al. PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl Cancer Inst. 93, 1246-1256 (2001). Excellent multivariate analysis of genetic alterations in malignant astrocytomas as they relate to patient outcome.
21. Leenstra S, Oskam NT, Bijleveld EH et al. Genetic subtypes of human malignant astrocytoma correlate with survival. Int. J. Cancer 79, 159-165 (1998).
22. Simmons ML, Lamborn KR, Takahashi M et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor and survival in glioblastoma patients. Cancer Res. 61, 1122-1128 (2001).
23. Newcomb EW, Cohen H, Lee SR et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 8, 655-667 (1998).
24. Shiraishi S, Tada K, Nakamura H et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95, 249-257 (2002).
25. Rasheed A, Herndon JE, Stenzel TT et al. Molecular markers of prognosis in astrocytic tumors. Cancer 94, 2688-2697 (2002).
26. Schmidt EE, Ichimura K, Reifenberger G et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54, 6321-6324 (1994).
27. Nishikawa R, Furnari FB, Lin H et al. Loss of P16INK4 expression is frequent in high-grade gliomas. Cancer Res. 55, 1941-1945 (1995).
28. Costello JF, Plass C, Arap W et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 57, 1250-1254 (1997).
29. Biernat W, Tohma Y, Yonekawa Y et al. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. (Berl). 94, 303-309 (1997).
30. Maruno M, Yoshimine T, Muhammad AK et al. Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications. J. Neuro-oncol. 30, 19-24 (1996).
31. Perry A, Anderl Y, Borell TJ et al. Detection of p16, RB, CDK4 and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am. J. Clin. Pathol. 112, 801-809 (1999).
32. Burton EC, Lamborn KR, Feuerstein BG et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res. 62, 6205-6210 (2002).
33. Kraus JA, Glesmann N, Beck M et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neuro-oncol. 48, 89-94 (2000).
34. Brat DJ, Seiferheld W, Perry A et al. Analysis of 1p, 19q, 9p and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from RTOG trials. Neuro-oncology 6, 96-103 (2004).
35. Ekstrand AJ, James CD, Cavenee WK et al. Genes for epidermal growth factor receptor, transforming growth factor alpha and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51, 2164-7212 (1991).
36. Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63, 6962-6970 (2003).
37. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol. Res. 12, 107-112 (2000).
38. Fujisawa H, Kurrer M, Reis RM et al. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am. J. Pathol. 155, 387-394 (1999).
39. Zhou XP, Li YJ, Hoang-Xuan K et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer. 84, 150-154 (1999).
40. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275, 1943-1947 (1997).
41. Kunwar S, Mohapatra G, Bollen A et al. Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res. 61, 7683-7688 (2001).
42. Tada K, Shiraishi S, Kamiryo T et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J. Neurosurg. 95, 651-659 (2001).
43. Balesaria S, Brock C, Bower M et al. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br. J. Cancer 81, 1371-1377 (1999).
44. Ganju V, Jenkins RB, O'Fallon JR et al. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic and molecular markers. Cancer 74, 920-927 (1994).
45. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90, 1473-1479 (1998). Demonstrates that 1p/19q codeletion in oligodendroglioma is predictive of a therapeutic response. A conceptual break through in neuro-oncology.
46. Glass J, Hochberg H, Gruber ML et al. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J. Neurosurg. 76, 741-745 (1992).
47. Jenkins RB, Curran W, Scott CB et al. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am. J. Clin. Oncol. 24, 506-508 (2001).
48. Hussein MR, Baidas S et al. Advances in diagnosis and management of oligodendroglioma. Expert Rev. AntiCancer Ther. 2, 520-528 (2002).
49. Smith JS, Perry A, Borell TJ, Lee HK et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645 (2000). Addresses the important issue of whether 1/p 19 loss in astrocytic neoplasms was predictive of therapeutic response. No survival differences were noted.
50. Perry A, Fuller CE, Banerjee R et al. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci. 8, 1-9 (2003).
51. Ino Y, Zlatescu MC, Sasaki H et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J. Neurosurg. 92, 983-990 (2002).
52. Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002). First article to show that gene expression profiles and computational algorithms can be used to successfully classify medulloblastomas and predict outcomes.
53. Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602-1607 (2003). First article to show that gene expression profilesand computational algorithms can be used to successfully classify glial neoplasms and predict outcome.
54. Tremont-Lukas I, Gilbert M. Advances in molecular therapies in patients with brain tumors. Cancer Control 10, 125-137 (2003). Reviews early results of clinical trials of targeted therapy agents.
55. Grossman SA, Fisher JD, Pdiantadosi S et al. The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: organization, objectives and activities. Cancer Control 5, 107-114 (1998). Reviews the organization structure of National Cancer Institute sponsored NABTT CNS Consortium in the USA.
56. Ciardiello F, Tortora G. Antiepidermal growth factor receptor drugs in cancer therapy. Expert Opin. Investig. Drugs 11, 755-768 (2002).
57. Eller JL, Longo SL, Hicklin DJ et al. Activity of antiepidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme, Neurosurgery 51, 1005-1014 (2002).
58. Moasser MM, Basso A, Averbuch SD et al. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61, 7184-7188 (2001).
59. Arteaga, CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa), Curr. Opin. Oncol. 13, 491-498 (2001).
60. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase, Cancer Res. 62, 2554-2560 (2002).
61. Lieberman FS, Cloughesy T, Malkin M et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Proc. Am. Soc. Clin. Oncol. 22, 105 (2003).
62. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133-142 (2004).
63. Prados M, Chang S, Burton E et al. Phase I study of OSI-774 alone or with temozolomide in patient with malignant glioma. Proc. Am. Soc. Clin. Oncol. 22, 99 (2003).
64. Hayahi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p12/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol. 7, 871-875 (1997).
65. Murthy YK, Thiemann JE, Coronelli C et al. Alanosine, a new antiviral and antitumour agent isolated from a Streptomyces. Nature 211, 1098-1199 (1966).
66. Gale GR, Schmidt GB. Mode of action of alanosine. Biochem. Pharmacol. 17, 363-368 (1968).
67. Graff JC, Plagermann PG. Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine mmonophosphae. Cancer Res. 36, 1428-1440 (1968).
68. University of California, San Diego (USCD) IND 52, 312 Annual Report to FDA, October, (2000).
69. Harland SP, Kuc RE, Pickard JD et al. Expression of endothelin (A) receptors in human gliomas and ameningiomas, with high affinity for the selective antagonist PD 156707. Neurosurgery 43 (4), 890-899 (1998).
70. Pagotto U, Arzberger T, Hopfine U et al. Cellular localization of endothelin receptor mRNAa (ETA and ETB) in brain tumors and normal human brain. J. Cardiovasc. Pharmacol. 26(Suppl. 3), 104-106 (1995).
71. Tsutsumi K, Niwa M, Kitagawa N et al. Enhanced expression of an endothelin ETA receptor in capillaries from human glioblastoma: a quantative receptor autoradiographic analysis using a radioluminographic imaging plate system. J. Neurochem. 63(6), 2240-2247 (1994).
72. Stiles JD, Ostrow PT, Balos LL et al. Correlation of endolthelin-1 and transforming growth factor-beta1 with malignancy and vascularity in human gliomas. J. Neuropath. Exp. Neurol. Exp. Neurol. 56 (4) 435-439 (1997).
73. Carducci MA, Nelson JB, Bowling MK et al. Atrasentran, an endothelin-receptor antagonist for refractory adenocarcinomas; safety and pharmacokinetics. J. Clin. Oncol. 20, 2171-2180 (2002).
74. Phuphanich S, Grossman SA, Lesser G et al. A phase I evaluation of the safety and pharmacokinetic (PK) of atransentan in adults with recurent malignant glioma; preliminary report. Proceedings of the 9th Annual Meeting of the Society for Neuro-Oncology. 18-21 (2004).
75. Rowinsky E, Windle J, Hoff Von DD et al. Ras protein farnesyltranferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17, 3631-3652 (1999).
76. Sklar M. The ras oncognes increase the intrinsic resistance of NIH 3R3 cells to ionizing radiation. Science 239, 645-647 (1988).
77. Pirollo KF, Tong YA, Villegas Z et al. Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat. Res. 135(2), 234-243 (1993).
78. McKenna WG, Weiss MC, Endlich B et al. Synergistic effect of of the v-myc oncogene with H-ras on radioresistance. Cancer Res. 50(1) 97-102 (1990).
79. McKenna WG, Iliakis G, Weiss MC et al. Increased G2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and vmyc. Radiat. Res. 125(3), 283-287 (1991).
80. Miller AC, Kariko K, Myers CE et al. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21 ras isoprenylatiob. Int. J. Cancer 53(2), 302-307 (1993).
81. Jackson J, Cochrane CG, Bourne JR et al. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl Acad. Sci. USA 87, 3042-3046 (1990).
82. Zhang F, Casey P. Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 65, 241-261 (1996).
83. Willumsen BM, Christensen A, Hubbert NL et al. The p21 ras C-terminus is required for transformation and membrane association. Nature 310(5978), 583-586 (1984).
84. Kato K, Cox AD, Hisaka MM et al. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 89, 6403-6407 (1992).
85. Kohn N, Omer CA, Conner MW et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1, 792-797 (1995).
86. James GL, Brown MS, Cobb MH, Goldstein JL. Benzodiazepine peptidomimetic BZA-5B interrupts the MAPK activation pathway in H-Ras-transformed Rat-1 cells but not in untransformed cells. J. Biol. Chem. 269(4), 9141-9251 (1994).
87. Kohl N, Wilson FR, Mosser SD. Protein farneyl transferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl Acad. Sci. USA 91, 9141-9251 (1994).
88. Nagusu T, Yoshimatsu K, Roswell C et al. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 55, 5310-5314 (1994).
89. Sun J, Qian AD, Hamilton AD, Sebti SM. Ras CAAX peptiodomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with k-ras mutation and p53 deletion. Cancer Res. 55, 4243-4247 (1995).
90. Sun J, Qian Y, Hamilton AD et al. Both farnesyltranferase and geranlygeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16(11), 1467-1473 (1998).
91. Sun J, Blaskovich MA, Knowles D et al. Antitumor efficacy of a novel class of nonthiol-containing peptidomimetic inhibitors of farnesyltransferase and geranlygeranyltranserase I: combination of therapy with the cytotoxic agents cisplatin, taxol and gemcitabine. Cancer Res. 59(19), 4919-4926 (1999).
92. Barrington RE, Subler MA, Rands E et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell Biol. 18(1), 85-92 (1998).
93. Sepp-Lorenzino L, Ma Z, Rands NE et al. A peptidomimetic inhibitorof farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55, 5302-5309 (1995).
94. Cloughesy TF, Kuhn J, Wen P et al. Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. 21, 317 (2002).
95. Kock H, Harris MP, Anderson SC et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int. J. Cancer 67, 808-815 (1996).
96. Cirielli C, Inyaku K, Capogrossi MC et al. Adenovirus-mediated wild type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J. Neurooncol. 43, 99-108 (1999).
97. Cheney IW, Johnson DE, Vaillancourt MT et al. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 58, 2331-2334 (1998).
98. Bykov VJ, Issaeva N, Shilov A et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 8, 282-288 (2002).
99. Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
100. Sarkaria JN, Tibbetts RS, Busby EC et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58, 4375-4382 (1998).
101. Shingu T, Yamada K, Hara N et al. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor. J. Neurosurg. 98, 154-161 (2003).
102. Zakhary R, Keles GE, Berger MS et al. Intraoperative imaging techniques in the treatment of brain tumors. Curr. Opin. Oncol. 11, 152-156 (1999).
103. Uhm JH, Dooley NP, Villemure JG et al. Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can. J. Neurol. Sci. 24, 3-15 (1997).
104. Fowler JF. Total dose in fractionated radiotherapy: implications of new radiobiologic data. Int. J. Radiat. Biol. 46, 103-122 (1984).
105. Walker MD, Breen SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N. Engl. J. Med. 303, 1323-1329 (1980).
106. Fine HA, Dear CB, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597 (1993).
107. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today 6, 157-162 (2000).
108. Berger MS, Leibel SA, Bruner JM et al. Primary central nervous system tumors of the supratentorial compartment. In: Cancer in the Nervous System. Levin VA (Ed.). Churchill Livingstone, NY, USA 57-126, (1996).
109. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70, 1781-1792 (1998).
110. Engelhard HH. Antisense oligodeoxynucleotide technology: potential use for the treatment of malignant brain tumors. Cancer Control 5, 163-170 (1998).
111. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-Oncology 2, 45-59 (2000).
112. Blasberg R, Molnar P, Groothius D et al. Concurrent measurements of blood flow and transcapillary transport in avian sarcoma virus-induced experimental brain tumors: implications for chemotherapy. J. Pharmacol. Exp. Ther. 231, 724-735 (1984).
113. Strasser JF, Fung LK, Eller S et al. Distribution of 1, 3-bis (2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J. Pharmacol. Exp. Ther. 275, 1647-1655 (1995).
114. Bouvier G, Penn RD, Kroin JS et al. Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 20, 286-291 (1987).
115. Walter KA, Tamargo RJ, Olivi A et al. Intratumoral chemotherapy. Neurosurgery 37, 1129-1145 (1995).
116. Bobo R, Laske D, Akbasak A et al. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91, 2076-2080 (1994).
117. Morrison PF, Chen MY, Chadwick RS et al. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter and tissue mechanics. Am. J. Physiol. 277(4 Pt 2), R1218-R1229 (1999).
118. Chen MY, Lonser RR, Morrison PF et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration and tissue-cannula sealing time. J. Neurosurg. 90(2), 315-320 (1999).
119. Lieberman D, Laske K, Morrison P et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82, 1021-1029 (1995).
120. Laske DW, Morrison PF, Lieberman DM et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J. Neurosurg. 87, 586-594 (1997).
121. Laske D, Youle R, Oldfield E et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med 12, 1362-1368 (1997). First report in new technology of convection-enhanced delivery on brain tumor.
122. Debinski W. Local treatment of brain tumors with targeted chimera toxin proteins. Cancer Invest. 20, 801-809 (2002).
123. Hall WA, Fostad O. Immunotoxins and central nervous system neoplasia. J. Neurosurg. 76, 1-12 (1992).
124. Debnski W, Obiri H, Pastan I et al. A novel chimeric protein composed of interleukin-13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin-13 and interleukin-4. J. Biol. Chem. 270, 16775-16780 (1995).
125. Debinski W, Miner R, Leland P et al. Receptor for interleukin-13 does not interact with IL4 but receptor for IL4 interacts with IL13 in human glioma cells. J. Biol. Chem. 271, 22428-22433 (1996).
126. Kunwar S, Pai L, Pastan I et al. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J. Neurosurg. 79, 569-576 (1993).
127. Debinski W, Obiri N, Powers S et al. Human glioma cells overexpress receptors for interleukin-13 and are extremely sensitive to a novel chimeric protein composed of interleukin-13 and pseudomonas exotoxin. Clin. Cancer Res. 1, 1253-1258 (1995).
128. Sampson JH, Akabani G, Archer GE et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neuro-Oncology 65, 27-35, (2003).
129. Weingart J, Strauss L, Grossman S et al. Phase I/II study: intra-tumoral infusion of IL-13PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neurooncology 4(Suppl. 1), S79 (2002).
130. Prados M, Lang F, Sherman J et al. Convection-enhanced delivery (CED) by positive pressure infusion for intra-tumoral and peritumoral administration of IL13-PE38QQR, a recombinant tumor-targeted cytotoxin in recurrent malignant gliomas. Neuro-oncology 4(Suppl. 1), S78, (2002).
131. Wong AJ, Bigner SH, Bigner DD et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA 84, 6899-6903 (1987).
132. Libermann TA, Razon N, Bartal D et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 44, 753-760 (1984).
133. Torp SH, Halsted E, Dalen A et al. Epidermal growth factor receptor expression in human gliomas. Cancer Immunol. Immunother. 33, 61-64 (1991).
134. Mesri EA, Kreitman RJ, Fu YM et al. Heparin-binding transforming growth factor α-Pseudomonas exotoxin A. A heparin modulated recombinant toxin cytotoxic to cancer cells and proliferation smooth muscle cells. J. Biol. Chem. 268, 4853-4862 (1993).
135. Lonser RR, Gogate N, Morrison P et al. Direct convective delivery of macromolecules to the spinal cord. Neurosurg. 89, 616-622 (1998).
136. Scherer H. Cerebral astrocytomas and their derivative. Am. J. Cancer 40, 159-198 (1940).
137. Lonser RR, Walbridge S, Garmestani K et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J. Neurosurg. 9, 905-913 (2002).
138. Rand R, Kreitman R, Patronas N et al. Intratumoral administration of recombinant circularly permitted interleukin-4-pseudomaonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 6, 2157-2165 (2000).
139. Kim D, Uttley D, Bell B et al. Comparisons of rates of infection of two methods of emergency ventricular drainage. J. Neurol. Neurosurg. Psychiatry 58, 444-446, (1995).
140. Samson JH, Akabani G, Archer G et al. Clinical outcome and distribution of a recombinant chimeric protein composed of transforming growth factor-α and a mutated Pseudomonas exotoxin (TP-38) via convection-enhanced microinfusion on a Phase I study for a malignant brain tumor. Proc. Am. Soc. Clin. Oncol. 22, 99 (2003).
141. Lorimer IAJ, Wikstrand CJ, Batra SK et al. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer Res. 1, 859-864 (1995).
142. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2. Expert Rev. AntiCancer Ther. 4(1) 105-128 (2004). Provides a good review of angiogenesis inhibitors; P13/Akr/phosphatidylinositol phosphate 3′-phosphatase, mTOR, SHH/PTCH and angiogenesis.
143. Van Meir EG, Bellail A, Phuphanich S. Emerging molecular therapies for brain tumors. Semin. Oncol. 31(2 Suppl. 4), 38-46 (2004). Excellent review of cell cycle control, angiogenesis, prodrug/suicide gene therapy and immunotherapy.